Cargando…

Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS)

SARS-CoV-2 binds to ACE2 receptors and enters cells. The symptoms are cough, breathlessness, loss of taste/smell and X-ray evidence of infiltrates on chest imaging initially caused by oedema, and subsequently by a lymphocytic pneumonitis. Coagulopathy, thrombosis and hypotension occur. Worse disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Melanie, Linden, Dermot, Earley, Olivia, Guo Parke, Hong, McAuley, Daniel Francis, Peto, Tunde, Taggart, Cliff, Kidney, Joe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Respiratory Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689398/ https://www.ncbi.nlm.nih.gov/pubmed/38035747 http://dx.doi.org/10.1136/bmjopen-2023-074726

Ejemplares similares

Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system
por: Bailey, Melanie, et al.
Publicado: (2023)

Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD
por: Linden, Dermot, et al.
Publicado: (2019)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014)

Mechanisms of Virus-Induced Airway Immunity Dysfunction in the Pathogenesis of COPD Disease, Progression, and Exacerbation
por: Guo-Parke, Hong, et al.
Publicado: (2020)

Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium
por: Guo-Parke, Hong, et al.
Publicado: (2022)

Airway Epithelium Senescence as a Driving Mechanism in COPD Pathogenesis
por: Bateman, Georgia, et al.
Publicado: (2023)

Effect of acetazolamide on obstructive sleep apnoea in highlanders: protocol for a randomised, placebo-controlled, double-blinded crossover trial
por: Tan, Lu, et al.
Publicado: (2022)

Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial
por: Jensen, Megan E, et al.
Publicado: (2019)

A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain)
por: Takahagi, Shunsuke, et al.
Publicado: (2023)

Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
por: Santucci, Stephanie, et al.
Publicado: (2014)

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase II, double-blind, randomised placebo-controlled trial
por: Lyu, Yee Ran, et al.
Publicado: (2018)

Shufeng Jiedu capsule for acute exacerbation of chronic obstructive pulmonary disease: a protocol of multicentre, randomised, double-blind, placebo-controlled trial
por: Xia, Ruyu, et al.
Publicado: (2023)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Effect of vitamin D(3) on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial
por: Vargas Buonfiglio, Luis G, et al.
Publicado: (2017)

The Impact of Aging in Acute Respiratory Distress Syndrome: A Clinical and Mechanistic Overview
por: Brown, Ryan, et al.
Publicado: (2020)

Improving access to health care for people with severe chronic obstructive pulmonary disease (COPD) in Southern New Zealand: qualitative study of the views of health professional stakeholders and patients
por: Stokes, Tim, et al.
Publicado: (2019)

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
por: Ware, Lorraine B, et al.
Publicado: (2023)

Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)
por: Matsuda, Yoshinobu, et al.
Publicado: (2021)

Evidence for chemokine synergy during neutrophil migration in ARDS
por: Williams, Andrew E, et al.
Publicado: (2017)

Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD
por: Martin, Allison, et al.
Publicado: (2021)

Prophylactic epinephrine for the prevention of transbronchial lung biopsy-related bleeding in lung transplant recipients (PROPHET) study: a protocol for a multicentre randomised, double-blind, placebo-controlled trial
por: Kalchiem-Dekel, Or, et al.
Publicado: (2019)

Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis
por: Morton, Miranda, et al.
Publicado: (2023)

Randomised placebo-controlled study of the effect of paracetamol on asthma severity in adults
por: Ioannides, Sally J, et al.
Publicado: (2014)

165 Early Versus Delayed Treatment of Swelling Attacks with Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With Hereditary Angioedema due to C1-INH Deficiency
por: Bork, Konrad, et al.
Publicado: (2012)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012)

Multiple doses of icatibant used during pregnancy
por: Kaminsky, Lauren W., et al.
Publicado: (2017)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
por: Hanania, Nicola A, et al.
Publicado: (2015)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation
por: Bourbeau, Jean, et al.
Publicado: (2016)

RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study
por: Power, Sharon, et al.
Publicado: (2017)

Can categorised values of maximal oxygen uptake discriminate patterns of exercise dysfunction in pectus excavatum: a prospective cohort study?
por: Satur, Christopher M R, et al.
Publicado: (2021)

Airway Inflammation and Host Responses in the Era of CFTR Modulators
por: Keown, Karen, et al.
Publicado: (2020)

Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design
por: Troosters, Thierry, et al.
Publicado: (2016)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Review of icatibant use in the Winnipeg Regional Health Authority
por: Cai, George, et al.
Publicado: (2020)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qa5fmscck32s0sc2vtfhvkq8mk